MCUR was noted as a reverse-merger candidate on this board when its only clinical program failed its second phase-3 trial in late 2015 (#msg-118037828). In the transaction outlined above, MCUR’s equity in the merged company derives from its remaining cash balance and its public listing.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.